Symptoms and esophageal motility based on phenotypic findings of scleroderma

Diseases of the Esophagus

Volumn 26, Issue 2, 2013, Pages 197-203

  Tang, D M ^a   Pathikonda, M ^a   Harrison, M ^a   Fisher, R S ^a   Friedenberg, F K ^a   Parkman, H P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pulmonary fibrosis; Raynaud's phenomenon; Scleroderma esophagus

Indexed keywords

ADULT; AMPLITUDE MODULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DYSPHAGIA; ENDOSCOPY; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS PH; FEMALE; GASTROSCOPE; HEARTBURN; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; LUNG FIBROSIS; MALE; PERISTALSIS; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; RAYNAUD PHENOMENON; SCLERODERMA; SCLERODERMA ESOPHAGUS; STOMACH EMPTYING; SYMPTOM; WHEEZING;

ADULT; DISEASE PROGRESSION; ESOPHAGEAL MOTILITY DISORDERS; FEMALE; HEARTBURN; HUMANS; MALE; MANOMETRY; MIDDLE AGED; PHENOTYPE; PULMONARY FIBROSIS; QUESTIONNAIRES; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 84872898298     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2012.01349.x     Document Type: Article

References (39)

1. Mayes M D. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54.
2. LeRoy E C, Black C, Fleischmajer R etal. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
3. Lomeo R M, Cornella R J, Schabel S I, Silver R M. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 1989; 87: 525-7.
4. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
5. Kavanaugh A, Tomar R, Reveille J, Solomon D H, Homburger H A. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000; 124: 71-81.
6. Gabrielli A, Avvedimento E V, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
7. D'Angelo W A, Fries J F, Masi A T, Shulman L E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-40.
8. McCarthy D S, Baragar F D, Dhingra S etal. The lungs in systemic sclerosis (scleroderma): a review and new information. Semin Arthritis Rheum 1988; 17: 271-83.
9. Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
10. Ebert E C. Esophageal disease in scleroderma. J Clin Gastroenterol 2006; 40: 769-75.
11. Mukhopadhyay A K, Graham D Y. Esophageal motor dysfunction in systemic diseases. Arch Intern Med 1976; 136: 583-8.
12. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994; 24: 29-39.
13. Orringer M B, Dabich L, Zarafonetis C J, Sloan H. Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications. Ann Thorac Surg 1976; 22: 120-30.
14. Tsianos E B, Drosos A A, Chiras C D, Moutsopoulos H M, Kitridou R C. Esophageal manometric findings in autoimmune rheumatic diseases: is scleroderma esophagus a specific entity? Rheumatol Int 1987; 7: 23-7.
15. Abell T L, Camilleri M, Donohoe K etal. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103: 753-63.
16. Tougas G, Eaker E Y, Abell T L etal. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000; 95: 1456-62.
17. Brennan P, Silman A, Black C etal. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 1993; 32: 357-61.
18. Kahaleh B, Meyer O, Scorza R. Assessment of vascular involvement. Clin Exp Rheumatol 2003; 21 (3 Suppl 29): S9-14.
19. Slobodin G, Rosner I, Rozenbaum M, Naschitz J E, Zuckerman E, Yeshurun D. Systemic sclerosis sine sclero derma: is it always the same disease? Report of three patients and discussion. Rheumatol Int 2002; 22: 170-2.
20. Slobodin G, Rosner I, Rozenbaum M etal. Systemic sclerosis sine scleroderma: comment on the article by Poormoghim etal. Arthritis Rheum 2000; 43: 2618.
21. Spechler S J, Souza R F, Rosenberg S J, Ruben R A, Goyal R K. Heartburn in patients with achalasia. Gut 1995; 37: 305-8.
22. Xue S, Katz P O, Banerjee P, Tutuian R, Castell D O. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
23. Mainie I, Tutuian R, Castell D O. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol 2008; 42: 676-9.
24. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell D O. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18: 370-3.
25. Janiak P, Thumshirn M, Menne D etal. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis - a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26: 1259-65.
26. Okamoto K, Iwakiri R, Mori M etal. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci 2003; 48: 2237-41.
27. Katsumoto T R, Whitfield M L, Connolly M K. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6: 509-37.
28. Fahey P J, Utell M J, Condemi J J, Green R, Hyde R W. Raynaud's phenomenon of the lung. Am J Med 1984; 76: 263-9.
29. Belch J J, Land D, Park R H, McKillop J H, MacKenzie J F. Decreased oesophageal blood flow in patients with Raynaud's phenomenon. Br J Rheumatol 1988; 27: 426-30.
30. Hostein J, Bost R, Carpentier P, Franco A, Fournet J. Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome. Gastroenterol Clin Biol 1985; 9: 130-5.
31. Hurwitz A L, Duranceau A, Postlethwait R W. Esophageal dysfunction and Raynaud's phenomenon in patients with scleroderma. Am J Dig Dis 1976; 21: 601-6.
32. Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest 1972; 51: 2663-8.
33. Stevens M B, Hookman P, Siegel C I, Esterly J R, Shulman L E, Hendrix T R. Aperistalsis of the esophagus in patients with connective-tissue disorders and Raynaud's phenomenon. N Engl J Med 1964; 270: 1218-22.
34. Halpern A, Kuhn P H, Shaftel H E etal. Raynaud's disease, Raynaud's phenomenon, and serotonin. Angiology 1960; 11: 151-67.
35. Christmann R B, Wells A U, Capelozzi V L, Silver R M. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010; 40: 241-9.
36. Savarino E, Bazzica M, Zentilin P etal. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179: 408-13.
37. Raghu G, Freudenberger T D, Yang S etal. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-42.
38. Bandeira C D, Rubin A S, Cardoso P F, Moreira Jda S, Machado Mda M. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2009; 35: 1182-9.
39. Richter J E. Review article: extraoesophageal manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22 (Suppl 1): 70-80.